Last reviewed · How we verify
NMN
NMN (nicotinamide mononucleotide) replenishes cellular NAD+ levels to support mitochondrial function and energy metabolism.
NMN (nicotinamide mononucleotide) replenishes cellular NAD+ levels to support mitochondrial function and energy metabolism. Used for Age-related metabolic decline, Mitochondrial dysfunction support.
At a glance
| Generic name | NMN |
|---|---|
| Also known as | Nicotinamide mononucleotide |
| Sponsor | Shanghai Cell Therapy Group Co.,Ltd |
| Drug class | NAD+ precursor / metabolic supplement |
| Target | NAD+ biosynthesis pathway |
| Modality | Small molecule |
| Therapeutic area | Aging / Metabolic Health / Longevity |
| Phase | FDA-approved |
Mechanism of action
NMN is a precursor to NAD+ (nicotinamide adenine dinucleotide), a critical coenzyme involved in cellular energy production, DNA repair, and stress response pathways. By increasing intracellular NAD+ availability, NMN aims to enhance mitochondrial function, improve metabolic efficiency, and support cellular resilience in aging-related conditions. This mechanism is thought to activate sirtuins and other NAD+-dependent enzymes that regulate longevity and metabolic health.
Approved indications
- Age-related metabolic decline
- Mitochondrial dysfunction support
Common side effects
- Gastrointestinal disturbance
- Headache
- Nausea
Key clinical trials
- Effect of NMN Supplementation on Organ System Biology (NA)
- PRecision gerOMedicinE: Tailored Healthy agEing With Lifestyle, sUpplements and drugS (PROMETHEUS) (NA)
- Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults (NA)
- Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery (PHASE2)
- NAD Augmentation in Diabetes Kidney Disease (PHASE2)
- Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program (PHASE2)
- NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome (PHASE1)
- Effect of NMN (Nicotinamide Mononucleotide) on Polycystic Ovary Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NMN CI brief — competitive landscape report
- NMN updates RSS · CI watch RSS
- Shanghai Cell Therapy Group Co.,Ltd portfolio CI